{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-023593","form_type":"8-K","ticker":"NUWE","cik":"0001506492","company_name":"Nuwellis, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.146180+00:00","generated_at":"2026-06-15T08:56:40.421149+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuwellis Q1 revenue down 5% to $1.8M; net loss widens to $6.5M","bullets":["Revenue $1.8M, 5% decline from $1.9M in Q1 2022; gross margin improved 120 bps to 58.4%.","Heart Failure segment revenue up 21% YoY; Pediatrics down 28%, Critical Care down 4%.","Net loss $6.5M ($5.76 loss per share) vs $4.5M ($42.45 loss per share) in prior year; includes $755K non-cash warrant revaluation expense.","Cash, equivalents and marketable securities $12.1M at March 31, 2023; no debt.","CEO cites new clinical evidence driving heart failure growth; focused on making Aquadex ultrafiltration therapy standard of care."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-023593","json":"https://secwatch.observer/filing/0001140361-23-023593.json","markdown":"https://secwatch.observer/filing/0001140361-23-023593.md","text":"https://secwatch.observer/filing/0001140361-23-023593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123023593/0001140361-23-023593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123023593/brhc20052638_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:56:40.421149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a5d45eca636fbfe969bbf46b08225a8f5246a57","claim":"Nuwellis, Inc. reported the first quarter ended March 31, 2023 results: revenue $1.8 million, net income $6.5 million, EPS a loss of $5.76 per basic and diluted common share.","evidence_excerpt":"technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2023. • Revenue of $1.8 million for the first quarter 2023, a 5% decrease over the prior-year period. • By segment, first quarter 2023 revenue in Heart Failure increased approximately 21% over the same period","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123023593/0001140361-23-023593-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$1.8 million"},{"label":"Net income","value":"$6.5 million"},{"label":"EPS","value":"a loss of $5.76 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}